2021
Cumulative burden of non-communicable diseases predicts COVID hospitalization among people with HIV: A one-year retrospective cohort study
Virata MD, Shenoi SV, Ladines-Lim J, Villanueva MS, Barakat LA. Cumulative burden of non-communicable diseases predicts COVID hospitalization among people with HIV: A one-year retrospective cohort study. PLOS ONE 2021, 16: e0260251. PMID: 34851963, PMCID: PMC8635326, DOI: 10.1371/journal.pone.0260251.Peer-Reviewed Original ResearchConceptsOne-year retrospective cohort studyCohort of PWHNon-communicable comorbiditiesPredictors of hospitalizationRetrospective cohort studyChronic lung diseaseLikelihood of hospitalizationSingle-site experienceCOVID-19 infectionNon-communicable diseasesOutcomes of peopleCohort studyHIV diseaseOverall mortalityClinical outcomesLung diseaseCardiovascular diseaseHospitalizationCumulative burdenHIVLater timeframeDiseaseEarly epidemicPWHOutcomesAlcohol Use and the Risk of Communicable Diseases
Morojele NK, Shenoi SV, Shuper PA, Braithwaite RS, Rehm J. Alcohol Use and the Risk of Communicable Diseases. Nutrients 2021, 13: 3317. PMID: 34684318, PMCID: PMC8540096, DOI: 10.3390/nu13103317.Peer-Reviewed Original ResearchConceptsCommunicable diseasesTreatment outcomesSevere acute respiratory syndrome coronavirus 2Respiratory infection/pneumoniaAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Alcohol useDisability-adjusted life yearsSyndrome coronavirus 2Poor treatment outcomesCOVID-19 infectionAlcohol use disorderGlobal health concernIndividual-level interventionsDifferent communicable diseasesTB deathsImmunodeficiency virusCoronavirus 2Severe illnessUse disordersPneumoniaHeavy drinkersLife yearsHIV researchTuberculosisDifferential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder
Mistler CB, Sullivan MC, Copenhaver MM, Meyer JP, Roth AM, Shenoi SV, Edelman EJ, Wickersham JA, Shrestha R. Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder. Journal Of Substance Use And Addiction Treatment 2021, 129: 108387. PMID: 34080555, PMCID: PMC8380664, DOI: 10.1016/j.jsat.2021.108387.Peer-Reviewed Original ResearchConceptsOpioid use disorderPublic health responseCOVID-19Use disordersHealth behaviorsNon-prescription drug useRacial-ethnic minoritiesCOVID-19-related impactsMental health statusHealth care accessSexual health behaviorsCOVID-19 testGreater financial burdenRace/ethnicitySample of peopleDirect adverse effectsDrug treatmentCare accessAlcohol consumptionDrug useHealth statusHealth responseHealth disparitiesRisk peopleCOVID-19 pandemic presents
2020
Social Support is Key to Retention in Care during Covid-19 Pandemic among Older People with HIV and Substance Use Disorders in Ukraine
Rozanova J, Shenoi S, Zaviryukha I, Zeziulin O, Kiriazova T, Rich K, Mamedova E, Yariy V. Social Support is Key to Retention in Care during Covid-19 Pandemic among Older People with HIV and Substance Use Disorders in Ukraine. Substance Use & Misuse 2020, 55: 1902-1904. PMID: 32666857, PMCID: PMC7523433, DOI: 10.1080/10826084.2020.1791183.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Retroviral AgentsBetacoronavirusComorbidityCoronavirus InfectionsCOVID-19FemaleHealth PersonnelHIV InfectionsHumansMaleMiddle AgedPandemicsPneumonia, ViralRetention in CareSARS-CoV-2Social IsolationSocial SupportSubstance-Related DisordersSurveys and QuestionnairesUkraineConceptsSubstance use disordersUse disordersHuman immunodeficiency virus HIVCOVID-19 pandemicOlder peopleLay health workersSocial supportTreatment interruptionConclusions/Health workersSUD treatmentPharmacological approachesYears old accountTelehealth supportVirus HIVHIVOlder adultsDisordersSuch interventionsPhone surveyTherapyProvision of supportCOVID-19 lockdownPandemicOld accountAttenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib
Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunocompromised HostLymphoma, T-CellMaleMiddle AgedNitrilesPandemicsPneumonia, ViralPyrazolesPyrimidinesSARS-CoV-2Severity of Illness IndexTransplantation, HomologousTreatment OutcomeConceptsAllogeneic hematopoietic stem cell transplant patientsHematopoietic stem cell transplant patientsSevere acute respiratory syndrome coronavirus 2SARS coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-2 pneumoniaAcute respiratory syndrome coronavirus 2Stem cell transplant patientsSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Coronavirus 2 infectionCell transplant patientsCoV-2 infectionStem cell transplantationSyndrome coronavirus 2High death rateImmunocompromised stateJAK/STAT inhibitor ruxolitinibTransplant patientsCell transplantationCoronavirus 2Novel therapiesInhibitor ruxolitinibPatientsDeath rateRuxolitinib